{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreib5ks5qheid6m6cgwd4x5qcaxe73clkemdxaa433smabs64kavu5u",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mo4gz22iici2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiga2azbu62lpj4xsvhtrwtc4f4ke7lyase3yowx7wpvlvrwym2n4i"
    },
    "mimeType": "image/jpeg",
    "size": 122846
  },
  "path": "/news/2026-06-fda-rapid-inhaled-insulin-children.html",
  "publishedAt": "2026-06-12T14:00:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 years and older who are living with type 1 or type 2 diabetes.",
  "title": "FDA approves rapid-acting inhaled insulin for children"
}